Capital Market Last Updated at December 9, 2021 09:50 IST
https://mybs.in/2ZjisUT
Venus Remedies rallied 9.92% to Rs 516.70 after the company received an approval from the Government of India under PLI 2.0 of the Production Linked Incentive (PLI) scheme for manufacturers of pharmaceutical goods registered in India.
Venus Remedies is one of the 10 non-MSME pharmaceutical companies under category-C which have been granted approval under the Production Linked Incentive (PLI) scheme. As per the scheme, the company will be eligible for incentive for the FY 2022-23 to 2027-28, subject to fulfilment of minimum investment criteria and based on incremental sales of eligible products as per the scheme guidelines. document.write(““);googletag.cmd.push(function(){googletag.defineOutOfPageSlot(‘/6516239/outofpage_1x1_desktop’,’div-gpt-ad-1490771277198-0′).addService(googletag.pubads());googletag.pubads().enableSyncRendering();googletag.enableServices();});
var banHeight=$(“.article-middle-banner iframe”).height();if(banHeight<=1){$(".article-middle-banner").height(0);$(".article-middle-banner").next().next().remove();}displayConBanner=1;
Venus Remedies’ consolidated net profit surged 77.7% to Rs 23.15 crore on a 60.7% jump in net sales to Rs 202.56 crore in Q2 FY22 over Q1 FY21.
Venus Remedies is a research and development driven global pharmaceutical company and among the leading injectable manufacturers in the world.
Powered by Capital Market – Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
PREVIOUS STORY
NEXT STORY
Copyrights © 2021 Business Standard Private Ltd. All rights reserved.
Upgrade To Premium Services
Business Standard is happy to inform you of the launch of “Business Standard Premium Services”
As a premium subscriber you get an across device unfettered access to a range of services which include:
Premium Services
In Partnership with 
Dear Guest,
Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.
Enjoy Reading!
Team Business Standard
